427 related articles for article (PubMed ID: 25840730)
1. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.
Legendre L; Barnetche T; Mazereeuw-Hautier J; Meyer N; Murrell D; Paul C
J Am Acad Dermatol; 2015 Jun; 72(6):992-1002. PubMed ID: 25840730
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.
Siegfried EC; Jaworski JC; Kaiser JD; Hebert AA
BMC Pediatr; 2016 Jun; 16():75. PubMed ID: 27267134
[TBL] [Abstract][Full Text] [Related]
3. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Arellano FM; Wentworth CE; Arana A; Fernández C; Paul CF
J Invest Dermatol; 2007 Apr; 127(4):808-16. PubMed ID: 17096020
[TBL] [Abstract][Full Text] [Related]
4. Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis.
Wu PC; Huang IH; Liu CW; Huang YC
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1265-1269. PubMed ID: 34390192
[TBL] [Abstract][Full Text] [Related]
5. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.
El-Batawy MM; Bosseila MA; Mashaly HM; Hafez VS
J Dermatol Sci; 2009 May; 54(2):76-87. PubMed ID: 19303745
[TBL] [Abstract][Full Text] [Related]
6. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas.
Draelos ZD
Curr Med Res Opin; 2008 Apr; 24(4):985-94. PubMed ID: 18284804
[TBL] [Abstract][Full Text] [Related]
7. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
8. Association Between the Use of Topical Calcineurin Inhibitors and the Risk of Cancer Among Patients with Atopic Dermatitis: A Nationwide, Population-Based, Retrospective Cohort Study.
Huang HH; Shen D; Chan TC; Cho YT; Tang CH; Chu CY
Am J Clin Dermatol; 2023 Sep; 24(5):799-808. PubMed ID: 37280416
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
10. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis.
Devasenapathy N; Chu A; Wong M; Srivastava A; Ceccacci R; Lin C; MacDonald M; Wen A; Steen J; Levine M; Pyne L; Schneider L; Chu DK;
Lancet Child Adolesc Health; 2023 Jan; 7(1):13-25. PubMed ID: 36370744
[TBL] [Abstract][Full Text] [Related]
12. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations.
Carr WW
Paediatr Drugs; 2013 Aug; 15(4):303-10. PubMed ID: 23549982
[TBL] [Abstract][Full Text] [Related]
13. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.
Paller AS; Fölster-Holst R; Chen SC; Diepgen TL; Elmets C; Margolis DJ; Pollock BH
J Am Acad Dermatol; 2020 Aug; 83(2):375-381. PubMed ID: 32246968
[TBL] [Abstract][Full Text] [Related]
14. Potent topical steroids are one of the treatments for cutaneous T-cell lymphoma.
Fernandez-Peñas P
J Allergy Clin Immunol; 2010 Aug; 126(2):414; author reply 414-5. PubMed ID: 20621338
[No Abstract] [Full Text] [Related]
15. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
16. Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis.
Hong CH; Gooderham M; Bissonnette R
J Cutan Med Surg; 2019; 23(4_suppl):5S-10S. PubMed ID: 31476937
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
Breuer K; Werfel T; Kapp A
Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
[TBL] [Abstract][Full Text] [Related]
18. Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma: A Systematic Review and Meta-analysis.
Lam M; Zhu JW; Tadrous M; Drucker AM
JAMA Dermatol; 2021 May; 157(5):549-558. PubMed ID: 33787818
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence.
Kalavala M; Dohil MA
Am J Clin Dermatol; 2011 Feb; 12(1):15-24. PubMed ID: 21067248
[TBL] [Abstract][Full Text] [Related]
20. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
